United States Health

BridgeBio Pharma (NASDAQ:BBIO) reported exploratory Phase 3 PROPEL 3 data showing 52 weeks of oral infigratinib treatment produced favorable trends versus placebo in children with achondroplasia.

Evotec (NASDAQ:EVO) initiated a first-in-human Phase 1 trial of JST-018, an investigational monoclonal antibody cocktail targeting orthopoxviruses developed by its Just – Evotec Biologics subsidiary.

BioVie (NASDAQ:BIVI) advanced regulatory discussions with the U.S. FDA for a Phase 3 development program evaluating bezisterim in Parkinson’s disease following Phase 2 SUNRISE-PD results.

Inhibrx Biosciences (NASDAQ:INBX) reported Phase 2 HexAgon trial results showing INBRX-106 combined with pembrolizumab achieved a 48.3% confirmed objective response rate in first-line head and neck cancer patients.

Abbott (NYSE:ABT) received U.S. FDA approval for its TactiFlex Duo Ablation Catheter, Sensor Enabled, a device designed to treat atrial fibrillation using pulsed field ablation and radiofrequency energy technologies.

AstraZeneca (NASDAQ:AZN) reported Phase III OBERON and TITANIA trial results showing tozorakimab reduced moderate and severe COPD exacerbations across broad patient populations while patients remained on standard inhaled treatment.

enGene Therapeutics (NASDAQ:ENGN) reported regulatory and clinical progress for detalimogene, including plans for a U.S. FDA pre-BLA meeting and initiation of a Biologics License Application submission in the fourth quarter of 2026.

Adlai Nortye (NASDAQ:ANL) dosed the first patient in Australia in a global Phase I trial evaluating AN4035, an antibody-drug conjugate designed to treat CEACAM5-enriched RAS-addicted solid tumors.

Bristol Myers Squibb (NYSE:BMY) reported positive Phase 2 QUINTESSENTIAL trial results for arlocabtagene autoleucel (arlo-cel) in adults with quadruple-class exposed relapsed and refractory multiple myeloma.

Pharvaris (NASDAQ:PHVS) reported Phase 3 CHAPTER-3 results showing once-daily oral deucrictibant XR reduced hereditary angioedema attack rates by 83% versus placebo across all HAE types after 24 weeks.

Roivant (NASDAQ:ROIV) reported Phase 2 PHocus trial results showing mosliciguat reduced pulmonary vascular resistance by 56.3% v

Belite Bio (NASDAQ:BLTE) submitted a New Drug Application in Japan for tinlarebant, an investigational once-daily oral therapy for Stargardt disease type 1, under Japan’s Sakigake Designation System.